Advanced Enzyme Technologies Limited (AETL) has transformed in to a global enzyme powerhouse based on research and technology development. AETL is largest Indian enzyme company engaged in the research and development manufacturing and marketing of 400+ proprietary products developed from over 68 indigenous enzymes and probiotics. AETL is one of the few manufacturers in the world who possess great depth and expertise in fermented enzymes manufacturing. The company caters to diversified industries and verticals like Human Nutrition Animal Nutrition and Bioprocessing. The company provides its proprietary enzyme products and customized enzyme solutions to various pharmaceutical and nutraceutical companies in India North America Asia (ex-India) Europe and other countries globally. The enzymes used by customers are as active ingredients in their pharmaceutical and nutraceutical formulations.AETL has state-of-the-art manufacturing facilities and research & development centers across India Germany and the US. The company has four wholly owned subsidiaries two subsidiaries and five step-down subsidiaries as on March 31 2019.The Company was incorporated as a private limited company on March 15 1989 under the provisions of the Companies Act 1956 as Advanced Biochemicals Private Limited in Maharashtra. Pursuant to a special resolution passed by the shareholders of the Company at the extra-ordinary general meeting held on April 21 1992 the Company was converted into a public limited company and consequently the name of our Company was changed to Advanced Biochemicals Limited. A fresh certificate of incorporation reflecting the new name was issued by the Registrar of Companies Maharashtra on May 28 1992. Pursuant to a special resolution passed by the shareholders of the Company at the extra-ordinary general meeting held on August 8 2005 the name of our Company was further changed from Advanced Biochemicals Limited to Advanced Enzyme Technologies Limited. A fresh certificate of incorporation reflecting the new name was issued by the Registrar of Companies Maharashtra Mumbai on August 19 2005.In 2011 the company took over Cal-India Foods International giving the company direct presence in USA.In 2012 the company took over Advanced Supplementary Technologies Corporation for consolidating its presence in USA.Advanced Enzyme Technologies Limited came out with its Initial Public Offer (IPO) of 4594875 Equity shares of Rs 10 each at an issue price of Rs 896 per Equity share ( Rs 810 per Equity share for eligible employees) consisting of fresh issue of 560405 Equity shares and an Offer for Sale of 4034470 Equity shares by Selling Shareholders. The IPO was open for subscription during the period from 20 July2016 to 22 July 2016. The said offer was overall subscribed 82.06 times. The equity shares of Advanced Enzyme Technologies Limited were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 1 August 2016 at an opening market price of Rs 1210 on both the exchanges compared with the IPO price of Rs 896 per share.During the financial year ended 31 March 2017 Advanced Enzyme Technologies Limited acquired 1.43 crore equity shares at Rs 35 per share of JC Biotech Private Limited (JCB) aggregating to Rs 50.08 crore 70% of the paid-up share capital of JCB. In view of this JCB became subsidiary with effect from December 1 2016.The sub-division of equity shares of the company from face value of 10 each to face value of 2 each (Stock Split) and consequent alteration in Capital Clause of Memorandum of Association of was approved by the company's shareholders on May 04 2017 through a Postal Ballot. The `Record Date' for the purpose of ascertaining the shareholders entitled to receive the said sub-divided equity shares was fixed by the Board as May 26 2017. Subsequently the company issued five (5) sub-divided equity shares of 2 each in lieu of one (1) equity share of 10 each to the eligible shareholders of the company.On 3 July 2017 Advanced Enzyme Technologies completed the acquisition of 200000 equity shares of MYR 1 (Malaysia Ringgit) each aggregating to MYR 200000 (equivalent to approx. 3134000) of AEM i.e. 80% of paid-up share capital of AEM. The company also subscribed to right issue of 150000 Equity Shares at MYR 1 per share of AEM aggregating to MYR 150000 (equivalent to 2602500) on 13 March 2018. On 20 March 2018 the company completed the acquisition of remaining stake i.e. 50000 equity shares of face value of MYR 1 each of AEM. The said acquisition was made at face value for a total consideration of MYR 50000 (equivalent to 867800). In view of the above AEM has become a wholly-owned subsidiary of the company effective from March 30 2018.Advanced Enzyme Technologies incorporated a wholly owned subsidiary Advanced Enzymes Europe BV (AEE) with issued share capital of Euro 2 Million [2000000 equity shares of EUR 1 each] (equivalent to approx. Rs 149.84 Million) in Netherlands on July 11 2017 mainly to expand your company's business in European Market. The company's wholly owned subsidiary Advanced Enzymes Europe BV completed the acquisition of 100% stake in evoxx technologies GmbH (evoxx) for a consideration of ? 6.57 million on August 15 2017. In view of above evoxx become a step-down subsidiary (100%) of the company.On 3 October 2017 the company's subsidiary Advanced Supplementary Technologies Corporation (ASTC) acquired certain assets and liabilities of Biomedic Labs LLC USA for a purchase consideration of USD 750000. The company has accounted for goodwill of USD 630000 equivalent to Rs. 40.98 Million on consolidation. During the financial year ended 31 March 2018 Advanced Enzyme Technologies subscribed to right issue of 189000 equity shares of 10 each at a premium of 27 per equity share aggregating to 6993000 of JC Biotech Private Limited (JCB). The shares have been duly allotted on January 31 2018. The purpose of Right Issue was mainly to meet the capital & operational expenditure of JCB. As the Right Issue was offered & subscribed by JCB's existing shareholders in proportionate to their respective shareholding in JCB the shareholding of Advanced Enzyme Technologies in JCB remains same i.e. 70%.